Where
San Francisco Marriott Union Square Hotel480 Sutter Street
San Francisco, CA 94109
Driving Directions
Contact
Joslin Diabetes Center - Professional Education888-567-5460
cme@joslin.harvard.edu
Here’s an all-too-common clinical scenario: Your patient using at least two antidiabetes medications is still quite far from A1C treatment goal, putting him or her at increased risk for complications and comorbidities. Why does this happen so often? The reasons are many, ranging from patient fear and reluctance to begin insulin to provider confusion about how to choose the best treatment options based on the pathophysiology of type 2 diabetes. And what do you do next? Add another pill, start insulin, try incretin therapy? If you start your patient on an injectable medication such as insulin or a GLP-1 agonist, will providing the necessary monitoring and patient support be too big a burden on your practice capabilities? Wrestling with these issues often results in glycemic control therapies being advanced more slowly than they ought to be, a situation called clinical inertia.
To help you overcome clinical inertia to provide better care for your patients, this symposium offers case-based learning on advancing therapy for type 2 diabetes when two antidiabetes medications are not working. Virtual patient case vignettes will demonstrate how to choose and when to advance therapies, highlighting how office-based systems can minimize the burden on your practice while maximizing treatment effectiveness.
But the sample cases will not be merely virtual; before the live activity, you’ll select 2 actual but anonymous patients from your own practice who fit the criteria for the patient type under discussion, record their current A1C levels and medications, and track their improvement over a 4- to 6-month period to help you translate the knowledge and skills you learn into the care of your real patients.
CME Information
Target Audience
This certified live activity has been developed for primary care providers and nondiabetes specialists and their clinical and office staff.
Topics
| 6:00 | PM | Registration and Dinner |
| 6:30 | Welcome, Opening Remarks, Pretest, and Description of Physician Performance Self-Training Exercise | |
| 6:45 | The Pathophysiology and Natural History of Type 2 Diabetes: Clinical Implications | |
| 7:05 | Pharmacologic Treatments for Type 2 Diabetes: An Overview of Action and Indications | |
| 7:25 | Virtual Patient 1: Metformin and Sulfonylurea, and Still Not at Goal | |
| 7:55 | Questions and Answers, Case 1 | |
| 8:05 | Virtual Patient 2: Obese, Basal Insulin and Metformin, and Still Not at Goal | |
| 8:35 | Questions and Answers, Case 2 | |
| 8:45 | Posttest, Next Steps for Physician Performance SAP, Moderator’s Concluding Remarks and Adjournment |
Learning Objectives
Participants will be provided with clinically relevant, evidence-based information. Upon completion of this activity, participants should be able to:
- Describe the pathophysiologic factors that contribute to the hyperglycemia of type 2 diabetes, and how they are manifest clinically
- Discuss the pharmacologic action of the major pharmacologic treatments for type 2 diabetes and their indications for usage
- Identify the goals of glycemic treatment for type 2 diabetes
- Demonstrate the ability to advance glycemic therapies for type 2 diabetes to the use of injectable therapies when initial treatments are not achieving recommended goals
- Patient-centered care
- Evidence-based practice
- Practice-based learning and improvement
Faculty
Speakers for this activity will be drawn from the distinguished faculty listed below.*
Richard S. Beaser, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Medical Executive Director, Professional Education
Joslin Diabetes Center
Boston, MA
Om P. Ganda, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Director, Lipid Clinic
Joslin Diabetes Center
Boston, MA
Osama Hamdy, MD, PhD, FACE
Harvard Medical School
Medical Director, Obesity Clinical Program
Joslin Diabetes Center
Boston, MA
Robert E. Heinig, MD
Clinical Professor of Medicine
University of Rochester Medical School
Chief of Endocrinology
Rochester General Hospital
Rochester, NY
Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
University of Miami
Miami, FL
Past President, American College of Endocrinology
American Association of Clinical Endocrinologists (AACE)
Philip Levy, MD, MACE
Clinical Professor of Medicine
University of Arizona College of Medicine
Phoenix, AZ
*Faculty list subject to change
Accreditation and Designation of Credit
Joslin Diabetes Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Joslin Diabetes Center designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME live activity was planned and produced in accordance with ACCME Essentials. Health professionals not eligible for continuing medical education credit will receive a certificate of participation that they may submit to their state licensing board for credit.
Disclosure Policy
It is the policy of Joslin Diabetes Center to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by Joslin Diabetes Center are required to present evidence-based data, identify and reference off-label product use, and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
This activity is supported by an educational grant from sanofi-aventis U.S.
Joslin Diabetes Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Joslin Diabetes Center designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits.™
